Investor Relations

Juno Therapeutics is building a fully integrated biopharmaceutical company focused on developing innovative cellular immunotherapies for the treatment of cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as solid tumors. Several product candidates have shown compelling clinical responses in clinical trials in refractory leukemia and lymphoma conducted to date. Juno's long-term aim is to leverage its cell-based platform to develop new product candidates that address a broader range of cancers and human diseases.

Download DocumentationJuno Corporate Presentation - August 2017

Recent News

Aug. 08, 2017Juno Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare ConferencePrinter Friendly Version
Aug. 03, 2017Juno Therapeutics Reports Second Quarter 2017 Financial ResultsPrinter Friendly Version
Jul. 27, 2017Juno Therapeutics to Report Second Quarter 2017 Financial Results on Thursday, August 3Printer Friendly Version
Jun. 17, 2017Juno Therapeutics Presents TRANSCEND NHL 001 Trial Data at International Conference on Malignant LymphomaPrinter Friendly Version

Upcoming Events

There are currently no events scheduled.

Past Events

08/15/17 3:40 p.m. ET
Juno Therapeutics at 2017 Wedbush PacGrow Healthcare Conference
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources